Section 32 Fund 2, LP 4
4 · Fulcrum Therapeutics, Inc. · Filed Jul 22, 2019
Insider Transaction Report
Form 4
Section 32 Fund 2, LP
10% Owner
Transactions
- Conversion
Common Stock
2019-07-22+464,285→ 464,285 total - Conversion
Series B Preferred Stock
2019-07-22−3,250,000→ 0 total→ Common Stock (464,285 underlying)
Footnotes (2)
- [F1]On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.